(0.29%) 5 114.87 points
(0.30%) 38 353 points
(0.34%) 15 982 points
(-0.94%) $83.06
(5.36%) $2.03
(0.31%) $2 354.50
(0.56%) $27.69
(4.29%) $961.70
(-0.26%) $0.932
(-0.45%) $10.97
(-0.58%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia...
Stats | |
---|---|
本日の出来高 | 230 501 |
平均出来高 | 427 591 |
時価総額 | 55.87M |
EPS | $0 ( 2024-03-26 ) |
次の収益日 | ( $-0.290 ) 2024-05-22 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.720 |
ATR14 | $0.00400 (0.62%) |
ボリューム 相関
BioLineRx Ltd. 相関
10 最も負の相関 | |
---|---|
AEY | -0.978 |
WNEB | -0.975 |
EDUC | -0.975 |
MLKN | -0.972 |
AGIL | -0.969 |
SCKT | -0.968 |
PBHC | -0.968 |
BSBK | -0.963 |
OBT | -0.963 |
NURO | -0.962 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
BioLineRx Ltd. 相関 - 通貨/商品
BioLineRx Ltd. 財務諸表
Annual | 2023 |
収益: | $4.80M |
総利益: | $174 000 (3.63 %) |
EPS: | $-0.940 |
FY | 2023 |
収益: | $4.80M |
総利益: | $174 000 (3.63 %) |
EPS: | $-0.940 |
FY | 2022 |
収益: | $0 |
総利益: | $-654 000 (0.00 %) |
EPS: | $-0.370 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.600 |
Financial Reports:
No articles found.
BioLineRx Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。